Intellia Therapeutics (NASDAQ:NTLA) CAO Sells $32,517.98 in Stock

Key Points

• Intellia Therapeutics' CAO, Michael Dube, sold 1,871 shares at $17.38 each, totaling approximately $32,518, reducing his stake in the company by 3.27%.
• The company reported a 104.3% increase in revenue year-over-year for the last quarter, with earnings per share of ($0.99), beating analyst expectations.
• Intellia Therapeutics has a market capitalization of $2.14 billion, with analysts giving it an average rating of "Hold" and a consensus price target of $27.39.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) CAO Michael Dube sold 1,871 shares of the stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the transaction, the chief accounting officer directly owned 55,266 shares of the company's stock, valued at approximately $960,523.08. The trade was a 3.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Intellia Therapeutics Trading Down 2.3%

NASDAQ:NTLA traded down $0.48 during midday trading on Friday, hitting $19.96. 5,779,676 shares of the company traded hands, compared to its average volume of 4,388,042. The firm has a market capitalization of $2.14 billion, a P/E ratio of -4.26 and a beta of 2.37. The firm's fifty day moving average is $12.76 and its 200-day moving average is $10.24. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $21.47.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The business had revenue of $14.25 million for the quarter, compared to the consensus estimate of $12.26 million. During the same quarter in the prior year, the firm posted ($1.52) earnings per share. The business's revenue for the quarter was up 104.3% on a year-over-year basis. On average, research analysts expect that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Institutional Trading of Intellia Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Benjamin Edwards Inc. boosted its holdings in Intellia Therapeutics by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company's stock worth $591,000 after buying an additional 1,126 shares in the last quarter. HighTower Advisors LLC grew its holdings in Intellia Therapeutics by 8.2% in the first quarter. HighTower Advisors LLC now owns 16,921 shares of the company's stock valued at $120,000 after purchasing an additional 1,282 shares during the period. Johnson Financial Group Inc. increased its position in shares of Intellia Therapeutics by 24.8% in the second quarter. Johnson Financial Group Inc. now owns 6,988 shares of the company's stock valued at $66,000 after buying an additional 1,388 shares in the last quarter. Harbour Investments Inc. raised its stake in shares of Intellia Therapeutics by 27.2% during the 2nd quarter. Harbour Investments Inc. now owns 6,633 shares of the company's stock worth $62,000 after buying an additional 1,419 shares during the period. Finally, Ameriprise Financial Inc. lifted its position in shares of Intellia Therapeutics by 13.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 11,803 shares of the company's stock valued at $111,000 after buying an additional 1,443 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company's stock.

Analysts Set New Price Targets

NTLA has been the topic of several recent research reports. JMP Securities reiterated a "market perform" rating on shares of Intellia Therapeutics in a report on Friday, September 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Intellia Therapeutics in a research note on Saturday, September 27th. Wells Fargo & Company reissued an "overweight" rating and set a $45.00 price target (down from $50.00) on shares of Intellia Therapeutics in a research report on Friday, August 8th. Wedbush reaffirmed a "neutral" rating and issued a $7.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 16th. Finally, Guggenheim reissued a "buy" rating and set a $14.00 target price on shares of Intellia Therapeutics in a research report on Wednesday, August 13th. Eleven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $27.39.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.